Deng_2019_Pak.J.Pharm.Sci_32_2091

Reference

Title : Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease - Deng_2019_Pak.J.Pharm.Sci_32_2091
Author(s) : Deng Y , Jiang Y , Zhao X , Wang J
Ref : Pak J Pharm Sci , 32 :2091 , 2019
Abstract :

With the recent research advances in molecular biology and technology multiple credible hypotheses about the progress of Alzheimer's disease (AD) have been proposed, among which the amyloid and cholinergic hypotheses are commonly used to develop reliable therapeutic agents. The multitarget-directed ligand (MTDL) approach was taken in this work to develop muilti-functional agents, which can mainly serve as dual beta-secretase (BACE 1) and Acetylcholinesterase (AChE) inhibitors. Series of new compounds were designed, synthesized and evaluated in this work, from which we identified 2-((4-(1,3-dioxoisoindolin-2-yl)benzyl)amino)-2-oxoethyl-2-(4-methoxyphenyl)aceta te (1h) as a new dual cholinesterase and beta-secretase inhibitor without toxicity.

PubMedSearch : Deng_2019_Pak.J.Pharm.Sci_32_2091
PubMedID: 31813875

Related information

Citations formats

Deng Y, Jiang Y, Zhao X, Wang J (2019)
Design, synthesis and biological Evaluation of Dual acetyl cholinesterase and beta-secretase inhibitors in treatment for alzheimer's Disease
Pak J Pharm Sci 32 :2091

Deng Y, Jiang Y, Zhao X, Wang J (2019)
Pak J Pharm Sci 32 :2091